|Articles|October 1, 2003
Blocking Agent
New York - A recent in vitro study uncovered specific details of the immunoregulatory agent, fontolizumab (HuZAFTM), showing the biologic modifier as able to block transcripts induced by the naturally occurring human protein, interferon-gamma, said Jules Cohen, M.D., at the International Psoriasis Symposium.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5














